Short Bowel Syndrome Market expected to reach US$2.6 bn by the end of 2024

The global short bowel syndrome market is consolidated. Shire Plc. held 50% of the market in 2015. Strategic acquisitions have become a strategy for key players. The players are also focused on marketing over-the-counter dietary supplements over-the-counter dietary supplements as well as manufacturing these supplements. Companies are also focusing on developing Innovative Therapies which Focus majorly on gastrointestinal diseases, states Transparency Market Research in its latest research on the global short bowel syndrome market. Names of the key players operating in the market are: Shire plc, Emmaus Life Sciences, Inc., Merck KGaA, and Nutrinia Ltd, OxThera, GlyPharma Therapeutics, Ardelyx, Inc., Sancilio & Company, Inc., Zealand Pharma A/S, and Naia Pharmaceuticals.

According to the research report, the global short bowel syndrome (SBS) market is expected to be worth US$2.6 bn by the end of 2024 and expand at a whopping CAGR of 30.4%. in the period from 2016 to 2024. On the basis of geography, North America is expected to exhibit at 32.7% CAGR from 2016 to 2024 and lead in the short bowel syndrome Market. In terms of drug class, the global short bowel syndrome market is expected to be led by the GLP-2 drug leaving behind glutamine and growth hormones. The GLP-2 drug is expected to expand at a whopping 36% CAGR between 2016 and 2024. This drug is sold both in the US and in the Europe under the brand name Gattex and Revestive respectively. Due to its exclusivity, GLP-2 drug is anticipated to contribute considerably to the revenues of the short bowel syndrome market worldwide.

Request A Sample-

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346

According to the lead author of this report, parenteral nutrition is extremely costly and is administered to the patient which allows into steins to maintain homeostasis and adapts to the changes and this unaffordability of parenteral nutrition will bolster the demand for short bowel syndrome drugs which reduce the patient’s dependence on parenteral nutrition. The growing incidences of short bowel syndrome is expected to drive the growth of this market. The additional assistance offered to patients suffering from short bowel syndrome through Gattex is also aiding the growth of the market. The increase in consumption of unhealthy and junk food, sedentary lifestyle, and busy lifestyle with no time to focus on nutritious and healthy food are some of the other factors that will help this market to grow further.

Leave a Reply